(Q37783296)

23 August 2017

title

Treatment options for multiple sclerosis: current and emerging therapies (English)

1 reference

23 August 2017

0 references

Kristen M Gawronski

1

1 reference

23 August 2017

Michelle M Rainka

series ordinal

2

1 reference

23 August 2017

Malti J Patel

series ordinal

3

1 reference

23 August 2017

Francis M Gengo

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

30

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

916-927

1 reference

Daclizumab treatment for multiple sclerosis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Quantitative risk-benefit analysis of natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Emerging monoclonal antibody therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Oral laquinimod for treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.9.916

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.9.916

1 reference

23 August 2017

1 reference